AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
about
ABL tyrosine kinases: evolution of function, regulation, and specificityNilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabPotential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemiaDelineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachChronic myeloid leukemia: reminiscences and dreamsManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentEfficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature ReviewFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsTen things you should know about protein kinases: IUPHAR Review 14Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDiscovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase InhibitorsDiscovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular ActivityDiscovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationDiscovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Ponatinib in refractory Philadelphia chromosome-positive leukemias.Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDFGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.Resistant mutations in CML and Ph(+)ALL - role of ponatinib.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsMolecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsFGF receptors: cancer biology and therapeuticsSustained proliferation in cancer: Mechanisms and novel therapeutic targetsRole of ABL family kinases in cancer: from leukaemia to solid tumoursAllosteric interactions between the myristate- and ATP-site of the Abl kinaseDynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro dataCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsSensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraDrug resistance missense mutations in cancer are subject to evolutionary constraintsATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance
P2860
Q24299738-60A7E1E8-C8A4-41F1-9514-198D0D07C218Q24299821-A4353C1E-F1AD-4699-97D7-F7AF3CD45A77Q24600031-1F1C00D2-EC26-4156-BB39-528C84F8F04EQ24629908-9EBD3ADA-F4C1-4467-8AF7-AB2351437E43Q24672143-35108EAE-DF5D-446D-B285-6AD9451856DEQ26748769-676A8E67-DAC9-46C3-9C58-555C342A3924Q26766299-9B8CD09B-E086-4BEC-A365-33BCA65F298FQ26775622-0397C78B-0024-4007-BFB9-5B5D4F069D33Q26801718-FBD0D37C-93E5-40D9-B0E8-818D7DE20CF2Q26849417-D517B6C6-805F-448D-A502-8F9465F6E2B1Q26849792-5E65056D-9B6B-48AA-B9BB-047C8298CD6DQ26866312-95EE5FC8-5F3B-4A24-B4EE-605948981E3AQ27025242-81DA5FB1-F015-429D-9985-87E5330B8641Q27028181-D7A748BE-8DF8-4751-B38B-DCAC84CF1927Q27660281-6725C75C-133D-49E2-AE24-7D68188B5114Q27667482-560929DD-BA9A-47EA-A8FA-F122DCEE32E0Q27683558-A387A9C1-CE22-447A-AF6D-06B6F7F64E44Q27684390-289CBEC9-57B4-496A-BD91-84290498364EQ27684879-A39DC5BB-DD41-4DF5-89A1-65211175E9C4Q27698001-84221E4A-AD8F-4540-B63B-E54D5DE9FEDCQ27712065-42CFFC16-7243-4741-93F6-7EA49A9B8AC2Q27851628-E6ABA7C5-2DEA-4A4D-AC6C-7696D6687B3DQ27851720-9AC9D0E1-6AFD-49BF-A7F9-C47657F7703FQ27851967-A0884845-1032-47F6-8677-D718E9EC15FFQ27852087-B1FBF238-621E-4F34-8BEF-B2EF7DD2C7EBQ27852999-FB5B57C3-255F-4BF1-8362-C56873D75260Q27853085-015380F9-770E-4AF9-9394-9E364D3639A2Q27853214-873E2BCA-EF43-42B4-8594-C873354F588BQ27853244-18633579-187D-488D-B465-525D18D23903Q28079232-9997A12E-ED25-4DA9-A99B-22493F485026Q28289859-5E7023C8-6170-4C8D-B4F0-400FA427E4FCQ28291186-ED5E841D-7063-4286-8273-3B3B114C1063Q28396388-E9AC3C94-1B7F-4159-AA14-6A87FD8F7D17Q28396643-1D0A726A-4D69-47FD-90D0-EF125246ABF8Q28476718-84070BDF-3CD0-4245-8F6C-AB3C0153B762Q28478542-2221A1AD-BCB5-411C-9625-9016B068A956Q28484913-E8CDC3C4-F5F4-4AE0-B6B7-E8622A9D5197Q28486093-E38C1765-1E2A-4985-9102-1BB264994D01Q28537830-78155ACC-34BB-4B7D-B6E1-9806B85AD2AAQ28540033-3627B079-7CA7-43BF-9104-441239CF7F42
P2860
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@ast
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@en
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@nl
type
label
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@ast
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@en
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@nl
altLabel
AP24534, a Pan-BCR-ABL Inhibit ...... omes Mutation-Based Resistance
@en
prefLabel
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@ast
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@en
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@nl
P2093
P2860
P921
P3181
P1433
P1476
AP24534, a pan-BCR-ABL inhibit ...... omes mutation-based resistance
@en
P2093
Amie S Corbin
Chester A Metcalf
Christopher A Eide
David C Dalgarno
Frank Wang
Jeffrey A Keats
Joseph Snodgrass
Lauren T Adrian
Lois Commodore
P2860
P304
P3181
P356
10.1016/J.CCR.2009.09.028
P407
P577
2009-11-06T00:00:00Z